JAMA Oncology Author Interviews

JAMA Network
  • 3,8 (11)
  • Y HỌC
  • HẰNG THÁNG

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

  1. Proportional Sedation for Persistent Agitated Delirium in Palliative Care

    31 THG 7

    Proportional Sedation for Persistent Agitated Delirium in Palliative Care

    Interview with David Hui, MD, and Eduardo Bruera, MD, authors of Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Proportional Sedation for Persistent Agitated Delirium in Palliative Care

    18 phút
  2. New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

    29 THG 5

    New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

    Interview with Thorir Einarsson Long, MD, PhD, and Ola Landgren, MD, PhD, authors of New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. Hosted by Vivek Subbiah, MD. Related Content: New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

    19 phút
  3. Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

    24 THG 4

    Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

    Interview with Shruti Gupta, MD, MPH, author of Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. Hosted by Vivek Subbiah, MD. Related Content: Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

    12 phút
  4. Accelerated Aging in Survivors of Childhood Cancer

    20 THG 3

    Accelerated Aging in Survivors of Childhood Cancer

    Interview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD. Related Content: Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer

    19 phút
  5. Academic-Community Partnership and Deaths in Promyelocytic Leukemia

    27 THG 2

    Academic-Community Partnership and Deaths in Promyelocytic Leukemia

    Interview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD. Related Content: Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality

    19 phút
  6. Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy

    30 THG 1

    Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy

    Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD. Related Content: Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy

    12 phút
  7. Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020

    05/12/2024

    Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020

    Interview with Katrina A. B. Goddard, PhD, author of Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. Hosted by Vivek Subbiah, MD. Related Content: Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020

    16 phút
  8. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

    21/11/2024

    Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

    Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

    19 phút
Xem tất cả (126)

Xếp Hạng & Nhận Xét

3,8
/5
11 Xếp hạng

Giới Thiệu

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

Thông Tin

  • Kênh
    JAMA Network
  • Nhà sáng tạo
    JAMA Network
  • Năm hoạt động
    2017 - 2025
  • Tập
    126
  • Xếp hạng
    Sạch
  • Bản quyền
    © 2024 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.
  • Trang web chương trình
    JAMA Oncology Author Interviews

Nội Dung Khác Của JAMA Network

Có Thể Bạn Cũng Thích